Federica Zoratto

Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to <i>KRAS</i> status: An Italian real-world study

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry

Clinicomics for Predicting HER2 Expression in Metastatic Colorectal Cancer: A Multicenter Machine Learning Analysis on Real-World Data

Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort

EP.11.20 Real World-Outcomes of Advanced Non-Squamous NSCLC Patients Treated With First-Line Chemo-Immunotherapy According to KRAS Status

Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed

Focus on human epidermal growth factor receptor 2 (HER2) positive metastatic colorectal cancer (HER2+ mCRC): A real world retrospective analysis.

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry

Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study

P-368 Efficacacy of trifluridine/tipiracil according to extended RAS evaluation: A multicenter retrospective analysis

P-236 Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS mutant metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort

P-249 Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS/BRAF wild type metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort

P-360 Efficacy of regorafenib according to extended RAS evaluation: A multicenter retrospective analysis

EP11.01-01 Final Analysis of First-Line Chemo-Immunotherapy in Patients with Advanced Lung Adenocarcinoma: An Italian Real-World Study

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Time-Dependent COVID-19 Mortality in Patients With Cancer

The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer

Smoking status during first‐line immunotherapy and chemotherapy in <scp>NSCLC</scp> patients: A case–control matched analysis from a large multicenter study

Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation

PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study

COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study

966P Diabetes therapy burden as proxy of impairment of immune checkpoint inhibitors efficacy